Experts Weigh In on Groceryshop 2021’s Most Important Trends

Groceryshop 2021 is expected to give all sides of the broader food & beverage industry a better understanding of how recent accelerations and disruptions have shaped food technologies. The exciting mix of professionals from pop-up shop innovators, to visual intelligence developers, to SaaS and delivery platforms will offer one of the first in-person blends of change for restaurants, grocers and more in over a year.

We decided to source some pre-show thoughts on what various cutting-edge professionals see as the most exciting trends at this year’s show, and how they see said trends intersecting with needs for better products, better marketing, better output, and a better food & beverage experience.

  • We called up our good friend, CEO & Founder of The Lionesque Group, and host of Retail Refined, Melissa Gonzalez, to chat labor, automation, and the brick & mortar shopping experience.
  • Predicting consumer behavior is at the top of the wishlist for nearly every major retailer. It used to come with a major price tag, but now AI and machine learning have become less expensive in some cases than traditional market research methods. Jehan Hamedi, CEO & founder of VIZIT, weighed in on how intelligence capabilities are helping brands create better products, packaging and imagery.
  • Big announcements on the SaaS platform side of the industry hit recently, as Zebra Technologies announced the acquisition of antuit.ai, a low-friction AI forecasting solution, to bring AI power to softwares as a service. We wanted to use this news as framing to better understand how machine learning will play a critical role in the future of forecasting in the grocery supply chain, so we sat down with Sivakumar Lakshmanan, CEO of antuit.ai, for his perspective on the merger and what’s next.
  • We also wanted perspectives on the last mile delivery trend accelerated last year by mass restaurant closures and quarantines. Grocery stores and restaurants alike were forced to decide: do they invest in their own in-house delivery services, or do they go with the established but sometimes profit-siphoning white label service instead? Where does technology play a role, and which investment is most sound depending on your size and available resources? Avi Friedman, head of logistics and delivery platforms at Via, a leader in TransitTech, weighed in.

 

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More